Prasugrel

Advances in Cardiology

Volumn 47, Issue , 2012, Pages 39-63

  Tello Montoliu, Antonio ^a   Tomasello, Salvatore D ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; HEPARIN; HIRULOG; OMEPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; R 138727; R 95913; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG RESEARCH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DIABETIC ANGIOPATHIES; DRUG INTERACTIONS; HUMANS; PATIENT SELECTION; PIPERAZINES; PLATELET AGGREGATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECURRENCE; THIOPHENES;

EID: 84865719767     PISSN: 00652326     EISSN: 16622839     Source Type: Book Series    
DOI: 10.1159/000338044     Document Type: Article

References (68)

1. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato J P, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO, American College of Cardiology Foundation/American Heart Associ ation Task Force on Practice Guidelines: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myo cardial Infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Associ ation Task Force on Practice Guidelines. Circulation 2009;120:2271-2306.
2. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato J P, Page RL, Riegel B, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction), American College of Emergency Physicians, Society for Cardio vascular Angiography and Interventions, Society of Thoracic Surgeons, American Association of Cardio vascular and Pulmonary Rehabilitation, Society for Academic Emergency Medicine: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Inter ventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardio vascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-e304.
3. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. Circulation 1998;98: 1597-1603.
4. Schomig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, ZitzmannRoth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
5. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L: Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoro-nary stenting (MATTIS). Circulation. 1998;98: 2126-2132.
6. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-1671.
7. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopi-dogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
8. Cadroy Y, Bossavy J P, Thalamas C, Sagnard L, Sakariassen K, Boneu B: Early potent antithrom-botic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial throm-bogenesis in humans. Circulation 2000;101:2823-2828.
9. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
10. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358: 527-533.
11. Sabatine MS, Cannon C P, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E, CLARITY-TIMI 28 Investigators: Addition of lopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189.
12. Chen ZM, Jiang LX, Chen Y P, Xie JX, Pan HC, Peto R, Collins R, Liu LS, COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group: Addition of clopidogrel to aspirin in 5,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-1621.
13. Sabatine MS, Cannon C P, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E, Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-1232.
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-1516.
15. Ferreiro JL, Angiolillo DJ: Clopidogrel response variability: current status and future directions. Thromb Haemost 2009;102:7-14.
16. 12 receptor inhibition: an update on clinical drug development. Am J Cardiovasc Drugs 2010;10:217-226.
17. Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, Ruterbories KJ, Kazui M, Farid NA: The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carbox-ylesterases 1 and 2. Drug Metab Dispos 2008;36: 1227-1232.
18. Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, Pang H: Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/ tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:169-179.
19. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE: Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-741.
20. Hagihara K, Kurihara A, Kawai K, Kazui M, Takahashi M, Kawabata K, Farid NA, Ikeda T: Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats. Xenobiotica 2007;37:788-801.
21. Smith RL, Gillespie TA, Rash TJ, Kurihara A, Farid NA: Disposition and metabolic fate of prasugrel in mice, rats, and dogs. Xenobiotica 2007;37:884-901.
22. Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ: The disposition of prasu-grel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-1104.
23. Wallentin L: P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30: 1964-1977.
24. Small DS, Farid NA, Payne CD, Jakubowski JA, Salazar DE, Winters KJ: Prasugrel 60 mg and clopi-dogrel 300 mg loading dose: a pharmacokinetic basis for the observed difference in platelet aggregation response (abstract). Am J Cardiol 2006;98(suppl 1):200M.
25. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F: The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar anti-platelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007;5:1545-1551.
26. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173.
27. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, PRINCIPLE-TIMI 44 Investigators: Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116: 2923-2932.
28. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30.
29. Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, Naganuma H, Li GY, Winters KJ: The platelet inhibitory effects and phar-macokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006;47:377-384.
30. 12 inhibitor: a single ascending dose study in healthy humans. Platelets 2006;17:209-217.
31. 12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007;63:421-430.
32. Payne CD, Li YG, Small DS, Ernest CS 2nd, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ: Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-562.
33. 12 inhibitor: a multiple-dose study in healthy humans. Platelets 2006;17:218-226.
34. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ: A comparison of prasugrel and clopi-dogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66. e9-66.e16.
35. Michelson AD, Frelinger AL 3rd, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos N P, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD, TRITON-TIMI 38 Investigators: Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009;30:1753-1763.
36. Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O, Henry P, Lim P, Beygui F, Collet J P, Marshall D, Luo J, Petitjean H, Drouet L: Prasugrel compared with high-dose clopi-dogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010;103:213-223.
37. Angiolillo DJ, Saucedo JF, DeRaad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh K, Effron MB: Increased platelet inhibition after switching from maintenance clopidogrel to prasug-rel in patients with acute coronary syndromes: Results of the Switching Anti Platelet (SWAP) study. J Am Coll Cardiol 2010;56:1017-1023.
38. Angiolillo DJ, Badimon J, Saucedo J F, Frelinger, AL, Michelson AD, Jakubowski, JA, Zhu B, Ojeh, CK, Baker B, Effron MB: Comparison of prasugel with clopidogrel on platelet function in coronary artery disease patients with type 2 diabetes mellitus-third optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS-3). Circulation 2009;120:S1027.
39. Wrishko RE, Ernest CS 2nd, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, Macias WL, Rohatagi S, Salazar DE, Antman EM, Wiviott SD, Braunwald E, Ni L: Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol 2009;49:984-998.
40. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-944.
41. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasu-grel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374: 989-997.
42. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS: Cytochrome P450 genetic polymorphisms and the response to prasug-rel: relationship to pharmacokinetic, pharmacody-namic, and clinical outcomes. Circulation 2009;119: 2553-2560.
43. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ: Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharma-codynamic response to clopidogrel but not prasug-rel. J Thromb Haemost 2007;5:2429-2436.
44. Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL: Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacody-namic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009;30:1744-1752.
45. Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA: Prasugrel versus clopidogrel for cytochrome P450 2C19 genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010;8:1678-1684.
46. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
47. 12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373.
48. O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD: The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) analysis. J Am Coll Cardiol 2009;54:678-685.
49. Capranzano P, Ferreiro JL, Angiolillo DJ: Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther 2009;7:361-369.
50. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E: Early and late benefits of prasug-rel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myo-cardial Infarction) analysis. J Am Coll Cardiol 2008; 51:2028-2033.
51. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E: Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758-2764.
52. Thygesen K, Alpert JS, White HD, for the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538.
53. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM, TRITON-TIMI 38 Investigators: Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353-1363.
54. Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E, TRITON-TIMI 38 Investigators: Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008;29:2473-2479.
55. Steinhubl SR, Berger PB, Mann JT III, et al: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
56. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, TRITON-TIMI 38 Investigators: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): doubleblind, randomised controlled trial. Lancet 2009;373: 723-731.
57. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon C P, Antman EM: Diabetes and mortality following acute coronary syndromes. JAMA 2007;298:765-775.
58. Angiolillo DJ: Antiplatelet therapy in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007;14:124-131.
59. Ferroni P, Basili S, Falco A, Davì G: Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004;2:1282-1291.
60. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-2435.
61. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Bass TA, Macaya C, Fernandez-Ortiz A: Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplate-let treatment. J Am Coll Cardiol 2006;48:298-304.
62. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708-716.
63. Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, Herdeg C, May AE, Gawaz M: Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30:372-374.
64. Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A: Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-1547.
65. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM, TRITON-TIMI 38 Investigators: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-1636.
66. Wiviott SD, Antman EM, Braunwald E: Prasugrel. Circulation 2010;122:394-403.
67. Mahoney EM, Wang K, Arnold S V, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ: Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010;121:71-79.
68. Trenk D, Stone G W, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ: A randomized trial of prasugrel versus clopi-dogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 2012 Apr 9 [Epub ahead of print].